Project objective: To improve the health care of Parkinson's disease patients in the ParkinsonNetz RheinMain+.
Hypothesis: Through the interdisciplinary and cross- sectoral networking in a tele medical network and the coordinating function of an "advanced practice nurse" (APN) specially trained for Parkinson's disease, the process quality within the network is increased and the individual health status is positively influenced.
Diagnosis of primary Parkinson's syndrome (G20.-) or atypical Parkinson's syndrome (G23.-, according to the current diagnostic criteria of the Movement Disorder Society, including the criteria of at least bradykinesia and rigidity or resting tremor must be present)
In the care regions of Hesse and Rhineland-Palatinate
Ability to give consent present
Severe depression
Psychoses or other psychiatric or medical comorbidities that could affect the smooth implementation of the study protocol (e.g.
Drug or alcohol addiction
Women who are pregnant or breastfeeding
Parallel
New Intervention form including
Other interventionThe central element of the new form of care is the implementation of a tele medical evaluation and coordination function, which controls individualized treatment processes within the network. The individualized evaluation and coordination of treatment paths is carried out within the already existing Parkinson's network RheinMain+ by a non-physician medical specialist (APN) specially trained for the indication Parkinson's disease.
Standard treatment
Other interventionThe standard treatment which all compulsory insured patients get.
Are there differences in the change in Parkinson's-specific quality of life after 12 months of observation between the intervention group and the controll group- operationalized by the PDQ-39
Parkinson´s Disease Quetionnaire -39 - to measure the differences in the change in Parkinson's-specific quality of life after 12 months of observation between the intervention group and the control group
Are there differences in the change in motor symptoms after 12 months of observation between the intervention group and the control group measured with the MDS-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS III)
MDS-UPDRS III- to measure the differences in the change in motor symptoms after 12 months of observation between the intervention group and the control group
Are there differences in the change in quality of life across diseases after 12 months of observation between the intervention and the control group measured with the European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-5L)
EQ-5D-5L- to measure the differences in the change in quality of life across diseases after 12 months of observation between the intervention group and the control group
Click on the lead sponsor to view all of their trials.
Johannes Gutenberg University Mainz
Lead sponsor
Hochschule für Wirtschaft und Gesellschaft Ludwigshafen Institut für Management, Ökonomie und Versorgung im Gesundheitsbereich
Collaborator
Katholische Hochschule Mainz Fachbereich Gesundheit und Pflege
Collaborator
Universitätsklinikum Frankfurt Zentrum der Neurologie und Neurochirurgie
Collaborator
Techniker Krankenkasse Landesvertretung Rheinland-Pfalz
Collaborator
DAK-Gesundheit Landesvertretung Rheinland-Pfalz und Saarland
Collaborator
